A Case of Extensive Alopecia Areata Following Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine with Favorable Outcome

    January 2023 in “ Journal of Cutaneous Immunology and Allergy ”
    Yoshihiro Matsuda, Yoshio Kawakami, Masaya Kawamoto, Yoji Hirai, Shin Morizane
    A 37-year-old woman experienced extensive alopecia areata following the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine, beginning with a low-grade fever on day 13 and progressing to widespread hair loss by day 22. With treatment using topical corticosteroids, her hair mostly regrew, leaving only one bald patch by day 310, indicating a favorable outcome.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results